Low-Cost, Group-Based Lifestyle Intervention Aids Diabetes Outcomes
By Lori Solomon HealthDay Reporter
THURSDAY, Aug. 15, 2024 -- Even individuals with a high genetic risk for type 2 diabetes (T2D) benefit from a low-cost, group-based intervention focused on healthy diet and physical activity, according to a study recently published online in the Journal of Clinical Endocrinology & Metabolism.
Maria Anneli Lankinen, Ph.D., from the University of Eastern Finland in Kuopio, and colleagues investigated whether a low or high genetic risk has effects on incident T2D in a group-based lifestyle intervention study. The analysis included men (aged 50 to 75 years) participating in the Metabolic Syndrome in Men cohort, with 315 characterized as having low genetic risk and 313 as having high genetic risk for T2D, as well as controls (196 low and 149 high genetic risk).
The researchers found that the three-year intervention significantly lowered the risk for T2D among the participants with a high genetic risk for T2D (hazard ratio, 0.30; 95 percent confidence interval, 0.16 to 0.56; P < 0.001). However, in the low genetic risk group, the effect was not significant (hazard ratio, 0.69; 95 percent confidence interval, 0.36 to 1.32; P = 0.262). Between the high and low genetic risk groups, the intervention effect was not significantly different. In both the low and high genetic risk groups, the intervention significantly ameliorated the worsening of glycemia and decreased weight.
"All individuals at risk of T2D should be encouraged to make lifestyle changes regardless of genetic risk," the authors write.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted August 2024
Read this next
GLP-1 Receptor Agonists Not Linked to Increased Risk of Psychiatric Adverse Events, Depression
MONDAY, May 19, 2025 -- For patients with overweight/obesity and/or diabetes, glucagon-like peptide 1 receptor agonist (GLP-1 RA) treatment is not associated with an increased...
Preoperative SGLT2 Inhibitor Users Have Increased Risk for Postoperative Euglycemic Ketoacidosis
TUESDAY, May 13, 2025 -- Patients using sodium-glucose cotransporter 2 inhibitors (SGLT2i) preoperatively have a slightly increased risk for postoperative euglycemic ketoacidosis...
GLP-1 Receptor Agonists Reduce Alcohol Intake in Patients Treated for Obesity
MONDAY, May 12, 2025 -- Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are tied to a reduction in alcohol intake, according to a research letter recently published in...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.